UPMC spending $2B to build 3 specialty hospitals

University of Pittsburgh Medical Center (UPMC) announced major expansion plans on Nov. 3, proposing to build three hospitals in its home city while not increasing the number of inpatient beds available.

According to the Pittsburgh Post-Gazette, the new facilities will be:

  • UPMC Vision and Rehabilitation Hospital, a 300,000-square-foot facility
  • UPMC Heart and Transplant Hospital at UPMC Presbyterian, a 15-story, 620-bed facility
  • UPMC Hillman Cancer Hospital, which will encompass a 240,000-square-foot patient tower and 160,000-square-foot outpatient center near Shadyside Hospital

UPMC said enough existing rooms in its facilities will be converted into office space and other uses so as to not increase the number of beds available in the region. More than 25 percent of UPMC’s existing beds are empty, according to the Pennsylvania health department.

The projects will cost $2 billion. The system had already announced other aggressive expansion plans, including a $900 million capital budget for 2018 and the acquisition of PinnacleHealth System earlier this year.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.